References
Antonazzo IC, Poluzzi E, Forcesi E, Salvo F, Pariente A, Marchesini G, De Ponti F, Raschi E (2019) Myopathy with DPP-4 inhibitors and statins in the real world: investigating the likelihood of drug-drug interactions through the FDA adverse event reporting system. Acta Diabetol. https://doi.org/10.1007/s00592-019-01378-7
Thakrar BT, Grundschober SB, Doessegger L (2007) Detecting signals of drug-drug interactions in a spontaneous reports database. Br J Clin Pharmacol 64:489–495
Ihle P, Dippel FW, Schubert I (2018) Statin-associated myopathy. Assessment of frequency based on data of all statutory health insurance funds in Germany. Pharmacol Res Perspect 6(3):e00404
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Both authors declare that there are no competing interests.
Additional information
Managed by Massimo Porta.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Appendix
Appendix
![figure a](http://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00592-019-01440-4/MediaObjects/592_2019_1440_Figa_HTML.png)
Rights and permissions
About this article
Cite this article
Kuss, O., Rathmann, W. A missed protective drug–drug interaction of DPP-4 inhibitors and statins on myopathy risk. Acta Diabetol 57, 113–114 (2020). https://doi.org/10.1007/s00592-019-01440-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00592-019-01440-4